0001437749-23-025311.txt : 20230906
0001437749-23-025311.hdr.sgml : 20230906
20230906163104
ACCESSION NUMBER: 0001437749-23-025311
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230831
FILED AS OF DATE: 20230906
DATE AS OF CHANGE: 20230906
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hollingsworth Jane H
CENTRAL INDEX KEY: 0001297141
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37942
FILM NUMBER: 231239601
MAIL ADDRESS:
STREET 1: DIFFUSION PHARMACEUTICALS INC.
STREET 2: 1317 CARLTON AVENUE, SUITE 200
CITY: CHARLOTTESVILLE
STATE: VA
ZIP: 22902
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CervoMed Inc.
CENTRAL INDEX KEY: 0001053691
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 300645032
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 20 PARK PLAZA
STREET 2: SUITE 424
CITY: BOSTON
STATE: MA
ZIP: 02216
BUSINESS PHONE: (617) 744-4400
MAIL ADDRESS:
STREET 1: 20 PARK PLAZA
STREET 2: SUITE 424
CITY: BOSTON
STATE: MA
ZIP: 02216
FORMER COMPANY:
FORMER CONFORMED NAME: Diffusion Pharmaceuticals Inc.
DATE OF NAME CHANGE: 20160115
FORMER COMPANY:
FORMER CONFORMED NAME: RestorGenex Corp
DATE OF NAME CHANGE: 20140307
FORMER COMPANY:
FORMER CONFORMED NAME: Stratus Media Group, Inc
DATE OF NAME CHANGE: 20080722
4
1
rdgdoc.xml
FORM 4
X0508
4
2023-08-31
0001053691
CervoMed Inc.
CRVO
0001297141
Hollingsworth Jane H
20 PARK PLAZA, SUITE 424
BOSTON
MA
02116
1
0
Common Stock
2023-08-31
4
M
0
122
A
943
D
Common Stock
2023-08-31
4
D
0
45
D
898
D
Restricted Stock Unit
2023-08-31
4
M
0
122
0
D
Common Stock
122
0
D
On August 31, 2023 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 77 Shares and (ii) $266.40 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $5.92. The award is now fully vested.
/s/ William R. Elder, attorney-in-fact for the Reporting Person
2023-09-06